C4 THERAPEUTICS, INC.

(CCCC)
  Report
Real-time Estimate Cboe BZX  -  05/26 10:48:06 am EDT
7.015 USD   +3.01%
05/16C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-Null Tumors
CI
05/16C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

C4 Therapeutics : BMO Capital Starts C4 Therapeutics at Outperform With $55 Price Target

03/31/2021 | 07:02am EDT


© MT Newswires 2021
All news about C4 THERAPEUTICS, INC.
05/16C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluat..
CI
05/16C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug
MT
05/16C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CF..
GL
05/09HC Wainwright Adjusts Price Target on C4 Therapeutics to $35 From $63, Reiterates Buy R..
MT
05/05C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
05/05C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
05/05C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highli..
GL
04/28Credit Suisse Initiates C4 Therapeutics at Underperform with $10 Price Target, Says Ris..
MT
04/18UBS Adjusts C4 Therapeutics Price Target to $26 From $64, Maintains Buy Rating
MT
More news
Analyst Recommendations on C4 THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 34,1 M - -
Net income 2022 -141 M - -
Net cash 2022 221 M - -
P/E ratio 2022 -2,47x
Yield 2022 -
Capitalization 332 M 332 M -
EV / Sales 2022 3,25x
EV / Sales 2023 3,88x
Nbr of Employees 121
Free-Float 86,9%
Chart C4 THERAPEUTICS, INC.
Duration : Period :
C4 Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends C4 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 6,81 $
Average target price 25,67 $
Spread / Average Target 277%
EPS Revisions
Managers and Directors
Andrew J. Hirsch President, Chief Executive Officer & Director
Lauren A. White Treasurer, Chief Financial & Accounting Officer
Marc A. Cohen Executive Chairman
Adam S. Crystal Chief Medical Officer
Stewart Fisher Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
C4 THERAPEUTICS, INC.-78.85%332
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232